Home

BROADWOOD PARTNERS, L.P.

CIK 1278386 · last filed 2026-04-20

BROADWOOD PARTNERS, L.P. is a corporate insider who has filed 67 SEC Form 4 insider transactions across 8 companies since 2007. The most recent filing shows the insider bought $2.0M of OCX on Apr 20, 2026. Across all open-market trades the lifetime net is −$179.1M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $784.5M across reported positions. The firm reports its address in New York, NY. 228 SEC filings were submitted jointly with BROADWOOD CAPITAL INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$784.52M

Companies

8

Total Filings

67

Lifetime Open-Market Net

-$179.07M

Filer Profile

Reported Address
BROADWOOD CAPITAL INC.
156 WEST 56TH STREET, 3RD FLOOR
NEW YORK, NY 10019
Phone
(212) 508-5735
State of Incorporation
DE
Formerly Known As
BROADWOOD PARTNERS LP (2004–2016)
Related Filers
BROADWOOD CAPITAL INC — 228 joint filings, latest 2026-04-27
Neal C Bradsher — 226 joint filings, latest 2026-04-27
Lineage Cell Therapeutics, Inc. — 73 joint filings, latest 2025-11-14
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Insight Molecular Diagnostics Inc. (OCX) Delisted 10%+ Owner 24,148,020 $3.20 $77.27M $137.03M 12 2026-04-20
STAA 10%+ Owner 30,907,258 $22.66 $700.36M -$233.92M 30 2026-01-13
LCTX Director 83,332,510 $1.01 $84.17M $21.00M 1 2024-02-08
Asterias Biotherapeutics, Inc. (AST) Delisted 10,584,312 — — $12.42M 1 2017-10-18
Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted Director 30,034,469 — — $22.26M 4 2017-10-17
QUESTCOR PHARMACEUTICALS INC (QCOR) Delisted Director 5,283,320 — — -$149.77M 3 2014-02-13
PALOMAR MEDICAL TECHNOLOGIES LLC (PMTI) Delisted 10%+ Owner 5,510,046 — — $8.00M 2 2012-05-31
COMARCO INC (CMRO) Delisted 10%+ Owner 2,655,910 — — $3.91M 12 2008-01-22

Recent Filings

67 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-04-20 Insight Molecular Diagnostics Inc. (OCX) Delisted Buy (P) +548,583 $1.96M EDGAR
2026-01-13 STAA Buy (P) +82,455 $1.82M EDGAR
2025-11-21 STAA Buy (P) +4,500,000 $123.18M EDGAR
2025-03-28 STAA Buy (P) +340,152 $5.95M EDGAR
2025-03-25 STAA Buy (P) +410,088 $7.24M EDGAR
2025-03-06 STAA Buy (P) +83,859 $1.45M EDGAR
2025-02-10 Insight Molecular Diagnostics Inc. (OCX) Delisted Buy (P) +15,497,085 $31.77M EDGAR
2025-01-16 STAA Buy (P) +88,128 $1.89M EDGAR
2024-12-18 STAA Buy (P) +240,600 $5.84M EDGAR
2024-10-04 Insight Molecular Diagnostics Inc. (OCX) Delisted Buy (P) +3,946,017 $11.63M EDGAR
Showing 1–10 of 67
Page 1 of 7
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.